Related Experiment Video
Updated: Jun 22, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Antimalarial activity of a cis-terpenone
D C Ghislaine Mayer1, Maimuna Bruce, Olga Kochurova
1Department of Biology, Virginia Commonwealth University, Richmond, Virginia 23284-2012, USA. gmayer@vcu.edu
Malaria Journal
|June 27, 2009
Summary
The novel compound oxidized hydroxy-cis terpenone (OHCT) effectively inhibits all malaria parasite stages, including drug-resistant strains, with no observed toxicity to human cells. This discovery offers a promising new avenue for malaria treatment.
Area of Science:
- Parasitology
- Medicinal Chemistry
- Drug Discovery
Background:
- Malaria remains a significant global infectious disease, necessitating new drug development due to parasite resistance.
- The oxidized derivative of hydroxy-cis terpenone (OHCT) is a synthetic molecule with demonstrated low toxicity to human liver cells.
- OHCT also inhibits cytochrome P450 enzymes, which are crucial for metabolizing many pharmaceutical drugs.
Purpose of the Study:
- To evaluate the antimalarial activity of OHCT against various strains of Plasmodium falciparum.
- To assess the toxicity of OHCT in cultured human liver cells.
- To investigate OHCT's potential impact on drug metabolism.
Main Methods:
- In vitro assays were performed to determine OHCT's efficacy against chloroquine-sensitive and -resistant Plasmodium falciparum strains.
- Activity was also tested against an artemisinin-resistant Plasmodium falciparum clone.
- Cytotoxicity was assessed using cultured human liver cells.
Main Results:
- OHCT demonstrated potent activity against all intraerythrocytic stages of Plasmodium falciparum at nanomolar concentrations.
- Efficacy was observed against both chloroquine-sensitive and -resistant strains, as well as an artemisinin-resistant clone.
- Significant activity was also noted against gametocytes, the parasite stage responsible for malaria transmission.
Conclusions:
- OHCT exhibits strong growth inhibitory effects on all Plasmodium falciparum stages with no detectable toxicity to human cells.
- The compound is readily synthesized and shows potential for use in combination therapies by modulating drug metabolism.
- OHCT represents a promising candidate for novel antimalarial drug development.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...